SEC Form 4 · accession 0001209191-17-039497

Cascadian Therapeutics, Inc. · CASC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 9, 2017

Accepted (ET)

Jun 13, 2017 · 4:39 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001412067

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jun 12, 2017	M	2,148	$0.00	A	52,148	D
Common Stock^F1	Jun 12, 2017	F	537	$3.34	D	51,611	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Share Unit (RSU)^F2,F3	—	Jun 9, 2017	A	13,927	A	—	—	Common Stock	13,927	13,927	D
Restricted Share Unit (RSU)^F2,F4	—	Jun 12, 2017	M	2,148	D	—	—	Common Stock	2,148	0	D

F1537 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 12, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 12, 2017 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person.
F2Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs.
F3100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances.
F4The RSU was 100% vested on June 12, 2017.